We encourage all people living with HIV in Europe to join this short study run by @shareeastlondon.bsky.social & @profchloeorkin.bsky.social to share their experiences with new HIV treatments & conversations with the clinical teams about treatment choices.

Visit the page & complete the survey below

🚨 Gilead’s lenacapavir could be a game-changer for #HIV — but at $28K/year, it’s priced out of reach for most.

Generics could cost <$50.

We’re calling on Gilead to make it affordable for all, not just the privileged few.

Please find UK-CAB public response below.

🚨 The Lenacapavir Early Access Programme has closed to new patients. This life-saving #HIV treatment is now out of reach for those who need it most.

We urge NHS England & Gilead to act now. Access to Lenacapavir must be restored. Urgently.

Community organisations: speak up. Silence costs lives.

UK-CAB deeply concerned about GSK/ViiV diversity policy implications globally, despite UK/EU assurances.

Erosion anywhere sets a dangerous precedent. Our community is alarmed by US policy shifts & PEPFAR threats.

Please read our statement below.

#HIV #Diversity #GlobalHealth #UKCAB

New @abpi.bsky.social guidance risks excluding #HIV advocates from conferences — suggesting we’re too “impressionable” to hear about treatments.

We reject this.

People with HIV are informed, critical partners in progress.

You can read our response below.

#NothingAboutUsWithoutUs #HIVAdvocacy